Monday, 20 May 2019

You are here

Rituximab May Halt ILD in Antisynthetase Syndrome Myositis

A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most. 

A retrospective analysis from the University of Pittsburgh and the Brigham and Women’s Hospital pooled their collective experience and analyzed data from 25 patients with AS-ILD, specifically assessing clinical, PFT, and chest CT outcomes using standardized scoring. 

All patients had antisynthetase antibodies (16 withJo-1, 6 PL-12, 3 PL-7). In 21/25 (84%), RTX was prescribed for recurrent or progressive ILD. CT findings included CT nonspecific interstitial pneumonia (NSIP; n = 13) and usual interstitial pneumonia (UIP)/fibrotic NSIP (n = 5), and 5 also had cryptogenic organizing pneumonia.

The 12 month outcomes, comparing pre- and post-RTX pulmonary variables, showed improvement in CT score (88%), FVC (79%), total lung capacity (from 56 ± 13 to 64 ± 13) the the glucocorticoid doses decreased from 18 ± 9 to 12 ± 12 mg/day.

DLCO (%) declined slightly at 1 year, but later increased from 42 ± 17 to 70 ± 20 at 3 years.

These uncontrolled and retrospective data provide preliminary evidence of RTX benefit when treating AS-ILD, a condition that is progressive in most patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Final Guidance on Interchangeability with Biosimilars

The FDA has published an industry guidance document to define interchangeability as regards to biosimilar use in the United States under section 351(k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(k)). 

Ustekinumab Effective in Behcet's Disease

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

Polypharmacy Blunts Responses and Ups the Safety Risks

A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.

RheumNowLive On Demand: Development & Use of JAK Inhibitors - Dr. John O'Shea

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

For RA With COPD, Abatacept is Safe

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a large claims-based analysis found.